U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H17N5O3
Molecular Weight 363.37
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERABELISIB

SMILES

NC1=NC2=C(O1)C=CC(=C2)C3=CN4C(=CN=C4C=C3)C(=O)N5CCOCC5

InChI

InChIKey=BLGWHBSBBJNKJO-UHFFFAOYSA-N
InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)

HIDE SMILES / InChI

Molecular Formula C19H17N5O3
Molecular Weight 363.37
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24915189 | https://www.ncbi.nlm.nih.gov/pubmed/28490463

Serabelisib (INK1117 and TAK-117) is an orally bioavailable, PI3K p110α- isoform-specific inhibitor with an in vitro IC50 of 15 nM, highly selective against other isoforms (p110β, p110γ, and p110δ) and mTOR (no significant inhibitions at 1 μM concentration). It displayed significant efficacy in several PI3Kα mutant-specific preclinical mouse xenograft tumor models, and blocked signaling to Akt and inhibited the growth of cancer cells harboring wild-type or mutated p110α. Preclinical studies showed TAK-117 to have the low potential for disrupting glucose metabolism or for causing cardiac adverse events; in rats and monkeys, doses up to 50 mg/kg/day were well tolerated. Serabelisib is currently under clinical evaluation.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
15.0 nM [IC50]
4500.0 nM [IC50]
1900.0 nM [IC50]
13900.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

In total, 24 patients were assigned to once-daily (6 at 100 mg, 6 at 150 mg, 8 at 200 mg, and 4 at 300 mg), 27 to Monday–Wednesday–Friday (MWF) (3 patients each at 200, 300, 400, and 600 mg, 12 at 900 mg, and 3 at 1,200 mg), and 20 to MTuW (3 patients each at 200, 400, and 600 mg, and 11 patients at 900 mg) dosing.
Route of Administration: Oral
SK-OV-3 and U87MG cell lines were obtained from ATCC. A total of 5000 cells/well in low serum media (0.2% FBS) were seeded in triplicate wells of a 96-well flat bottom culture plate for 18 h to adhere. Media was aspirated and inhibitors in 0.2% FBS media were added to each well at the indicated concentrations. After 48 h, cell viability was determined using the MTS assay (Cell Titer 96 Aqueous One solution cell proliferation assay kit; Promega) with absorbance (490 nm) measured in a microplate spectrophotometer.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:27:12 GMT 2023
Edited
by admin
on Sat Dec 16 05:27:12 GMT 2023
Record UNII
43J9Q56T3W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERABELISIB
INN   WHO-DD  
INN  
Official Name English
MLN-1117
Code English
INK-1117
Code English
serabelisib [INN]
Common Name English
Serabelisib [WHO-DD]
Common Name English
AGN-PC-0DB6FL
Code English
METHANONE, (6-(2-AMINO-5-BENZOXAZOLYL)IMIDAZO(1,2-A)PYRIDIN-3-YL)-4-MORPHOLINYL-
Systematic Name English
(6-(2-AMINO-5-BENZOXAZOLYL)IMIDAZO(1,2-A)PYRIDIN-3-YL)-4-MORPHOLINYLMETHANONE
Systematic Name English
INK1117
Code English
MLN1117
Code English
TAK-117
Code English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
NCI_THESAURUS C2152
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
Code System Code Type Description
CAS
1268454-23-4
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
CAS
1428967-74-1
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
NO STRUCTURE GIVEN
NCI_THESAURUS
C98844
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545379
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
PUBCHEM
70798655
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
SMS_ID
100000174654
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
FDA UNII
43J9Q56T3W
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
DRUG BANK
DB14935
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545055
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
INN
10369
Created by admin on Sat Dec 16 05:27:12 GMT 2023 , Edited by admin on Sat Dec 16 05:27:12 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Selective, oral bioavailable PI3Kα isoform inhibitor s more than 100-fold selective than other class I PI3K isoforms and mTOR as well as a high degree of selectivity against a large panel of protein kinases with potential antitumor activity.
IC50
Related Record Type Details
ACTIVE MOIETY